Modified magnesium and lipoproteins in children with attention deficite hyperactivity disorder (ADHD)

World Journal of Biological Psychiatry

Volumn 12, Issue SUPPL. 1, 2011, Pages 63-65

  Irmisch, Gisela ^a   Thome, Johannes ^a   Reis, Olaf ^a   Häßler, Frank ^a   Weirich, Steffen ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

ADHD; Fatty acids; Lipids; Lipoproteins; Magnesium

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; PHOSPHOLIPID; TRIACYLGLYCEROL;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; HUMAN; MAGNESIUM BLOOD LEVEL; MALE; PHOSPHOLIPID BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; SCHOOL CHILD; STRESS; TRIACYLGLYCEROL BLOOD LEVEL;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHOLESTEROL, HDL; FATTY ACIDS; HUMANS; LIPIDS; LIPOPROTEINS; MAGNESIUM; MALE; REFERENCE VALUES;

EID: 80052770433     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.600292     Document Type: Article

References (22)

1. Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. 2006. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 75:299-308. (Pubitemid 44442911)
2. Bekaroglu M, Aslan Y, Gedik Y. Deger O, Mocan H, Erduran E, Karahan C. 1996. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 37:225-227. (Pubitemid 26093391)
3. Bourre JM. 2006. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 2: macronutrients. J Nutr Health Aging 10:386-399. (Pubitemid 44845349)
4. CGI (Clinical Global Impressions). 1976. National Institute of Mental Health Early Clinical Drug Evaluation, Psychopharma-cology Research Branch. p. 217-222.
5. Charach G, Kaysar N, Grosskopf I, Rabinovich A, Weintraub MJ. 2009. Methylphenidate has positive hypocholesterolemic and hypotriglyceridemic effects: new data. Clin Pharmacol 49: 848-851.
6. Conners CK. 1969. A teacher rating scale for use in drug studies with children. Am J Psychiatry 126:884-888.
7. Curtis LT, Patel K. 2008. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): a review. J Altern Complement Med 14:79-85. (Pubitemid 351185434)
8. Galland L. 1991-1992. Magnesium, stress and neuropsychiatric disorders. Magnes Trace Elem 10:287-301. (Pubitemid 23109479)
9. Häß ler F, Dück A, Reis O, Buchmann J. 2007. " Alternative " pharmakologische Therapien bei ADHS. Psychopharmako-therapie 14:229-236. (Pubitemid 350188486)
10. Hamer M, Stamatakis E. 2009. Physical activity and mortality in men and women with diagnosed cardiovascular disease. Eur J Cardiovasc Prev Rehabil 16:156-160.
11. Huss M, Völp A, Stauss-Grabo M. 2010. Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems-an observational cohort study. Lipids Health Dis 24:105.
12. Irmisch G, Wiechert P, Häß ler F, Langemann I. 1992. Fatty acid patterns of serum lipids and the hypermotoric syndrome. Neurosciences 18:77-80.
13. Kirby A, Woodward A, Jackson S, Wang Y, Crawford MA. 2010. Childrens' learning and behaviour and the association with cheek cell polyunsaturated fatty acid levels. Res Dev Disabil 31:731-742.
14. Korsten-Reck U, Kromeyer-Hauschild K, Korsten K, Baumstark MW, Dickhuth HH, Berg A. 2008. Frequency of secondary dyslipidemia in obese children.Vasc Health Risk Manage 4:1089-1094.
15. Levant B, Zarcone TJ, Fowler SC. 2010. Developmental effects of dietaryn-3 fatty acids on activity and response to novelty. Physiol Behav 101:176-183.
16. Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. 2006. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. Magn Res 19:46-52. (Pubitemid 43945610)
17. Nogovitsina OR, Levitina EV. 2007. Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol 37:199-202. (Pubitemid 46453519)
18. Rucklidge JJ, Johnstone J, Kaplan BJ. 2009. Nutrient supplementation approaches in the treatment of ADHD. Expert Rev Neurother 9:461-476.
19. Schwartz RD, Wagner JP, Yu X, Martin D. 1994. Bidirectional modulation of GABA-gated chloride channels by divalent cations: inhibition by Ca 2+ and enhancement by Mg 2+. J Neurochem 62:916-922.
20. Sinn N. 2007. Physical fatty acid deficiency signs in children with ADHD symptoms. Prostaglandins Leukot Essent Fatty Acids 77:109-115. (Pubitemid 47539104)
21. Spahis S, Vanasse M, Bélanger SA, Ghadirian P, Grenier E, Levy E. 2008. Lipid profile, fatty acid composition and pro-and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 79:47-53.
22. Tierney E, Conley SK, Goodwin H, Porter FD. 2010. Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome. Am J Med Genet A 152A:91-95.